Asengeprast

N/A

Report date: 2025/04/08 09:04:54
NMEFirst In Class

Base Information

Drug NameAsengeprast
Drug Alias NameSHP-627FT-011FT-11
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTransforming growth factor beta inhibitorsPlatelet-derived growth factor subunit B inhibitorsOvarian cancer G-protein coupled receptor 1 inhibitors
TargetsTransforming growth factor betaPlatelet-derived growth factor subunit BOvarian cancer G-protein coupled receptor 1
Therapy Area/IndicationsScleroderma, DiffuseScleroderma, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUkrainePolandNetherlands +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFibrotech Therapeutics Pty LtdUniversity Of Melbourne
China Registration ClassN/A

Develop Information

Active CompaniesCerta Therapeutics Pty Ltd
Inactive CompaniesN/A
Active IndicationsScleroderma, DiffuseScleroderma, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A